Таксаны в лечении рака молочной железы


В.Ф. Семиглазов (1), Г.А. Дашян (1), В.В. Семиглазов (2), Р.М. Палтуев (1), Т.Ю. Семиглазова (1), Р.В. Донских (1), К.С. Николаев (1), А.В. Комяхов (1), К.Ю. Зернов (1), П.В. Криворотько (1)

(1) ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, Санкт-Петербург (2) Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова МЗ РФ, Санкт-Петербург
Рассматриваются современные подходы к применению таксанов (паклитаксел и доцетаксел) в терапии рака молочной железы (РМЖ). Результаты многочисленных исследований свидетельствуют, что таксан-содержащая химиотерапия способствует улучшению ближайших и отдаленных результатов лечения всех стадий РМЖ и всех его биологических подтипов, за исключением ранних (операбельных) стадий люминального А РМЖ. Рассматриваются перспективы применения представителя нового поколения таксанов – препарата наб-паклитаксел (Абраксан®), более эффективного по сравнению со стандартным паклитакселом.

Литература


1. Семиглазов В.Ф., Нургазиев К.Ш., Семиглазов В.В., Дашян Г.А., Палтуев Р.М., Семиглазова Т.Ю., Криворотько П.В., Николаев К.С. Руководство: Общие рекомендации St. Gallen 2015 по лечению раннего рака молочной железы (адаптированные экспертами Российского Общества Онкомаммологов

2. Albain K.S., Barlow W.E., Ravdin P.M., Farrar W.B., Burton G.V., Ketchel S.J., Cobau C.D., Levine E.G., Ingle J.N., Pritchard K.I., Lichter A.S., Schneider D.J., Abeloff M.D., Henderson I.C., Muss H.B., Green S.J., Lew D., Livingston R.B., Martino S., Osborne C.K. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9707):2055–63.

3. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., Martino S., Perez E.A., Muss H.B., Norton L., Hudis C., Winer E.P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–67.

4. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., Davidson N.E., Martino S., Livingston R., Ingle J.N., Perez E.A., Carpenter J., Hurd D., Holland J.F., Smith B.L., Sartor C.I., Leung E.H., Abrams J., Schilsky R.L., Muss H.B., Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003;21:1431–39.

5. Coates A.S., Winer E.P., Goldhirsch A., Gelber R.D., Gnant M., Piccart-Gebhart M., Thürlimann B., Senn H.J.; Panel Members. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 2015;26:1533–46.

6. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007;13:4429–34.

7. Drukker C.A., Bueno-de-Mesquita J.M., Retèl V.P., van Harten W.H., van Tinteren H., Wesseling J., Roumen R.M., Knauer M., van ‘t Veer L.J., Sonke G.S., Rutgers E.J., van de Vijver M.J., Linn S.C. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer. 2013;133:929–26.

8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.

9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R., Davies C., Godwin J., Gray R., Pan H.C., Clarke M., Cutter D., Darby S., McGale P., Taylor C., Wang Y.C., Bergh J., Di Leo A., Albain K., Swain S., Piccart M., Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials. Lancet. 2012;379:432–44.

10. González-Martín A., Alba E., Ciruelos E., Cortés J., Llombart A., Lluch A., Andrés R., Álvarez I., Aramendía J.M., de la Peña F.A., Barnadas A., Batista N., Calvo L., Galve E., García-Palomo A., García-Sáenz J.Á., de la Haba J., López R., López-Vivanco G., Martínez-Jáñez N., de Dueñas E.M., Plazaola A., Rodríguez-Lescure Á., Ruiz M., Sánchez-Rovira P., Santaballa A., Seguí M.Á., Tusquets I., Zamora P., Martín M. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr. Cancer Drug Targets. 2015;15:1–16.

11. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005;23(31):7794–803.

12. Hart C.D., Sanna G., Siclari O., Biganzoli L., Di Leo A. Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. Breast. 2015;24(Suppl 2):S136–42.

13. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., Ingle J.N., Cooper M.R., Hayes D.F., Tkaczuk K.H., Fleming G., Holland J.F., Duggan D.B., Carpenter J.T., Frei E. 3rd, Schilsky R.L., Wood W.C., Muss H.B., Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003;21(6):976–98.

14. Hudis C., Citron M.L., Berry D., et al. Five year follow-up of INT C9741: Dose-dense (DD) chemo-therapy (CRx) is safe and effective. Breast Cancer Res. Treat. 2005;94(suppl 1):S20, abstr. 41.

15. Jatoi I., Anderson W.F., Jeong J.H., Redmond C.K. Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J. Clin. Oncol. 2011;29:2301–304.

16. Joensuu H., Kellokumpu-Lehtinen P.L., Huovinen R., Jukkola-Vuorinen A., Tanner M., Kokko R., Ahlgren J., Auvinen P., Paija O., Helle L., Villman K., Nyandoto P., Nilsson G., Pajunen M., Asola R., Poikonen P., Leinonen M., Kataja V., Bono P., Lindman H. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J. Clin. Oncol. 2012;30:11–8.

17. Joensuu H., Kellokumpu-Lehtinen P.L., Huovinen R., Jukkola-Vuorinen A., Tanner M., Asola R., Kokko R., Ahlgren J., Auvinen P., Hemminki A., Paija O., Helle L., Nuortio L., Villman K., Nilsson G., Lahtela S.L., Lehtiö K., Pajunen M., Poikonen P., Nyandoto P., Kataja V., Bono P., Leinonen M., Lindman H.; FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol. 2009;10:1145–51.

18. Jones S., Holmes F.A., O’Shaughnessy J., Blum J.L., Vukelja S.J., McIntyre K.J., Pippen J.E., Bordelon J.H., Kirby R.L., Sandbach J., Hyman W.J., Richards D.A., Mennel R.G., Boehm K.A., Meyer W.G., Asmar L., Mackey D., Riedel S., Muss H., Savin M.A. Docetaxel with cyclo-phosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of US Oncology research trial 9735. J. Clin. Oncol. 2009;27:1177–83.

19. Jones S.E., Savin M.A., Holmes F.A., O’Shaughnessy J.A., Blum J.L., Vukelja S., McIntyre K.J., Pippen J.E., Bordelon J.H., Kirby R., Sandbach J., Hyman W.J., Khandelwal P., Negron A.G., Richards D.A., Anthony S.P., Mennel R.G., Boehm K.A., Meyer W.G., Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 2006;24:5381–87.

20. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G.N., Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008;26:1275–81.

21. Mackey J.R., Martin M., Pienkowski T., Rolski J., Guastalla J.P., Sami A., Glaspy J., Juhos E., Wardley A., Fornander T., Hainsworth J., Coleman R., Modiano M.R., Vinholes J., Pinter T., Rodríguez-Lescure A., Colwell B., Whitlock P., Provencher L, Laing K, Walde D, Price C, Hugh J.C., Childs B.H., Bassi K., Lindsay M.A., Wilson V., Rupin M., Houé V., Vogel C. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14:72–80.

22. Mamounas E.P., Bryant J., Lembersky B., Fehrenbacher L., Sedlacek S.M., Fisher B., Wickerham D.L., Yothers G., Soran A., Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 2005;23(16):3686–96.

23. Martin M., López-Tarruella S. Optimizing Adjuvant Taxanes in Early Breast Cancer. J. Clin. Oncol. 2015;33(21):2334–36.

24. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., Tomiak E., Al-Tweigeri T., Chap L., Juhos E., Guevin R., Howell A., Fornander T., Hainsworth J., Coleman R., Vinholes J., Modiano M., Pinter T., Tang S.C., Colwell B., Prady C., Provencher L., Walde D., Rodriguez-Lescure A., Hugh J., Loret C., Rupin M., Blitz S., Jacobs P., Murawsky M., Riva A., Vogel C. Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 2005;352:2302–13.

25. Martín M., Rodríguez-Lescure A., Ruiz A., Alba E., Calvo L., Ruiz-Borrego M., Munárriz B., Rodríguez C.A., Crespo C., de Alava E., López García-Asenjo J.A., Guitián M.D., Almenar S., González-Palacios J.F., Vera F., Palacios J., Ramos M., Gracia Marco J.M., Lluch A., Alvarez I., Seguí M.A., Mayordomo J.I., Antón A., Baena J.M., Plazaola A., Modolell A., Pelegrí A., Mel J.R., Aranda E., Adrover E., Alvarez J.V., García Puche J.L., Sánchez-Rovira P., Gonzalez S., López-Vega J.M.; GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J. Natl. Cancer Inst. 2008;100:805–14.

26. Martín M., Seguí M.A., Antón A., Ruiz A., Ramos M., Adrover E., Aranda I., Rodríguez-Lescure A., Grosse R., Calvo L., Barnadas A., Isla D., Martinez del Prado P., Ruiz Borrego M., Zaluski J., Arcusa A., Muñoz M., López Vega J.M., Mel J.R., Munarriz B., Llorca C., Jara C., Alba E., Florián J., Li J., López García-Asenjo J.A., Sáez A., Rios M.J., Almenar S., Peiró G., Lluch A. Adjuvant docetaxel for high-risk, node-negative breast cancer. N. Engl. J. Med. 2010;363:2200–10.

27. Olivotto I.A., Bajdik C.D., Ravdin P.M., Speers C.H., Coldman A.J., Norris B.D., Davis G.J., Chia S.K., Gelmon K.A. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 2005;23(12):2716–25.

28. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E. Jr, Wickerham D.L., Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006;24(23):3726–34.

29. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 1996;14(10):2738–46.

30. Sparano J. Long-term follow-up of the E1199 phase III trial evaluating the role of the taxane and schedule in operable breast cancer. J. Clin. Oncol. 2015;33:2353–60.

31. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., Wolff A.C., Sledge G.W. Jr, Wood W.C., Davidson N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 2008;358(16):1663–71.

32. Untch M., Jackisch C., Schneeweiss A., Conrad B., Aktas B., Denkert C., Eidtmann H., Wicbringhaus H., Kümmel S., Hilfrich J., Warm M., Paepke S., Just M., Hanusch C., Hackmann J., Blohmer J.U., Clemens M., Darb-Esfahani S., Schmitt W.D., Dan Costa S., Gerber B., Engels K., Nekljudova V., Loibl S., von Minckwitz G. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016;17(3):345–56.

33. www.accessdata.fda.gov/drugsatfda_docs/label/2012/021660s031lbl.pdf

34. Blum J.L., Savin M.A., Edelman G., Pippen J.E., Robert N.J., Geister B.V., Kirby R.L., Clawson A., O’Shaughnessy J.A. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer. 2007;7:850–56.

35. Инструкция к медицинскому применению препарата Абраксан: ЛСР-009047/10-120816


Об авторах / Для корреспонденции


К.С. Николаев – к.м.н., научный сотрудник, врач-онколог хирургического отделения опухолей молочной железы ФГБУ "НИИ онкологии им. Н.Н. Петрова" Минздрава России, Санкт-Петербург, kirill.nikolaev87@gmail.com


Похожие статьи


Бионика Медиа